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G
lioblastoma (GB) remains one of the
most lethal cancers in humans with
a median survival after maximal
therapy of less than 2 years after ﬁrst diag-
nosis.13 Despite improvements in the past
few decades with intraoperative surgical
techniques, chemotherapy, and radiation
therapy, predictable curative treatment for
GB does not exist yet. New insights into
speciﬁc genemutations and dysregulated sig-
naling pathways of the pathogenesis of brain
tumors4,5 have highlighted gene therapy as a
potential approach for the treatment of GB.
This approach is based on the local delivery of
a vector or nanoparticle carrying genetic ma-
terial to cause overexpression of a gene or
replace a gene that is missing or under-ex-
pressed in order to kill cancer cells.6
Approaches to gene therapy for GB in-
clude the following : (1) delivery of suicide
genes, which convert pro-drugs in situ
and cause tumor cell death;7 (2) delivery
of cytokine genes, which mobilize immune
cells to ﬁght the tumor;8,9 (3) delivery of
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ABSTRACT Biodegradable polymeric nanoparticles have the
potential to be safer alternatives to viruses for gene delivery;
however, their use has been limited by poor eﬃcacy in vivo. In this
work, we synthesize and characterize polymeric gene delivery
nanoparticles and evaluate their eﬃcacy for DNA delivery of herpes
simplex virus type I thymidine kinase (HSVtk) combined with the
prodrug ganciclovir (GCV) in a malignant glioma model. We
investigated polymer structure for gene delivery in two rat glioma
cell lines, 9L and F98, to discover nanoparticle formulations more
eﬀective than the leading commercial reagent Lipofectamine 2000. The lead polymer structure, poly(1,4-butanediol diacrylate-co-4-amino-1-butanol) end-
modiﬁed with 1-(3-aminopropyl)-4-methylpiperazine, is a poly(β-amino ester) (PBAE) and formed nanoparticles with HSVtk DNA that were 138( 4 nm in
size and 13( 1 mV in zeta potential. These nanoparticles containing HSVtk DNA showed 100% cancer cell killing in vitro in the two glioma cell lines when
combined with GCV exposure, while control nanoparticles encoding GFP maintained robust cell viability. For in vivo evaluation, tumor-bearing rats were
treated with PBAE/HSVtk infusion via convection-enhanced delivery (CED) in combination with systemic administration of GCV. These treated animals
showed a signiﬁcant beneﬁt in survival (p = 0.0012 vs control). Moreover, following a single CED infusion, labeled PBAE nanoparticles spread completely
throughout the tumor. This study highlights a nanomedicine approach that is highly promising for the treatment of malignant glioma.
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tumor-suppressor genes, which induce apoptosis in
tumor cells;10,11 and (4) delivery of conditionally repli-
cating viruses to speciﬁcally lyse tumor cells while
sparing normal tissue.12,13 Gene therapy has most
often been performed using viral carriers. However,
viruses pose signiﬁcant safety risks due to their inher-
ent toxicity, immunogenicity, and tumorigenicity.14
Nonviral gene delivery vectors have traditionally
been unable to match the eﬃcacy of viral gene
delivery;15 however, they can be engineered to avoid
the risks that viruses pose. Nonviral methods of gene
delivery have recently expanded and several eﬀective
nanomaterials exist including lipid-based,16,17 poly-
meric,1820 and inorganic2123 nanoparticles, some
of which have reached clinical trials.24 Successful
DNA delivery can be achieved by designing mate-
rials that can overcome extra- and intracellular
barriers.2528 Cationic, primary amine-containing poly-
mers such as poly(L-lysine) (PLL) can bind anionic DNA
and compact it into positively charged nanoparticles.
This protects the DNA and promotes cellular uptake via
the electrostatic interaction between the cationic
nanoparticle and anionic cell surface.28,29 Tertiary
amine-containing polymers with high buﬀering capac-
ities, such as poly(ethylenimine) (PEI), enable endo-
cytosis and are then able to escape the endosome via
the proton sponge mechanism.29 DNA release can be
achieved by hydrolytic polymer degradation in the
cytoplasm of the cell following escape from the
endosome. Poly(β-amino ester)s (PBAEs) are a class of
polymers that can be engineered to contain primary,
secondary, and tertiary amines and hydrolytically cleav-
able ester bonds.30 These chemical properties enable
eﬀective DNA binding, endocytosis, endosomal es-
cape, and intracellular DNA release within minutes to
hours, all of which are prerequisite to nuclear uptake of
the DNA3133 PBAEs have previously been shown to
be safe and eﬀective DNA delivery vectors in vitro to
several cell types and in vivo to retinal and brain tumor
tissue.3234 In previous studies, we have also shown
that these polymers degrade quickly under physiolog-
ical conditions, with a half-life of only a few hours.35
We believe that this is important both to minimize
potential nanoparticle cytotoxicity as well as to ensure
successful release of the DNA cargo.35 Interestingly,
PBAEs can also be engineered to exhibit cell-type
speciﬁcity and to selectively transfect tumor tissue
while avoiding surrounding healthy tissue.34,36 These
advantages make this class of polymers a promising
option to use for the fabrication of polymeric gene
delivery nanoparticles for the treatment of brain
tumors. Convection-enhanced delivery (CED) has
recently been shown to be eﬀective for the delivery
of polymeric nanoparticles encapsulating small mole-
cule drugs, such as dithiazanine iodide, Doxil, and
O6-benzylguanine, to brain tumors.3739 Moreover,
CED and gene therapy have been suggested as a
promising combination for the treatment of glioma.40
Speciﬁcally, CED leads to better volumeof distribution by
maintaining a pressure gradient which enhances diﬀu-
sion throughout the tumormass.41Wehypothesized that
intratumoral infusion via CEDmay represent an eﬀective
approach for the delivery of PBAE/DNA nanoparticles, as
they are “soft” nanocomplexes which can be deformed
and may more easily be convected though small spaces
while encapsulating large DNA molecules.
The present study investigates the eﬃcacy of PBAE
nanoparticles for the intracellular delivery of the
herpes simplex virus (HSV)-derived enzyme thymidine
kinase (HSVtk), which acts as a suicide gene in an
aggressive gliosarcoma model. Suicide therapy is
based on the systemic delivery of an inactive prodrug
with tumor-speciﬁc expression of a drug-activating
enzyme (the suicide gene)42 in order to avoid toxicity
in normal cells. The HSVtk-ganciclovir system has been
previously used for gene therapy in several viral ap-
proaches such as with nonreplicating herpes virus or
adenovirus.4345 HSVtk catalyzes the phosphorylation
of the cytotoxic nucleoside analogue ganciclovir (GCV)
that can be incorporated into the DNA of actively
proliferating cells, which disrupts DNA replication
and halts cell division.46,47 Since the prodrug nucleo-
sides are poor substrates for mammalian thymidine
kinase, the toxic eﬀect is initially restricted to cancer
cells, as active GCV kills proliferating cells only.48 An
attractive aspect of the HSVtk/GCV enzyme/prodrug
system is that this therapy beneﬁts from the phenom-
enon known as “bystander eﬀect”, whereby even
cancer cells that do not express HSVtk become sensi-
tive to GCV due to the activation of GCV in neighboring
transfected cancer cells.49,50
This work presents a biodegradable nanomedicine
capable of eﬀectively and selectively delivering DNA to
malignant glioma in vivo. A library of PBAE nanoparti-
cles was evaluated in vitro to optimize DNA delivery
while minimizing toxicity. The optimal nanoparticle
formulation was then physically characterized. We de-
monstrate that these nanoparticles can deliver an HSVtk
transgene in vitro and initiate glioma cell killing via the
local activation of GCV.We also demonstrate transfection
of malignant gliomas in vivo. Using this nanoparticle-
based therapy, we were able to statistically improve
survival of rats with malignant glioma (Scheme 1). This
work presents an exciting frontier in nanomedicine with
signiﬁcant potential to treat malignant gliomas.
RESULTS AND DISCUSSION
PBAE-Based Nanoparticles Show High in Vitro Gene Delivery
to Glioma Cells. A library of poly(β-amino ester)s (PBAEs)
was synthesized following methods that we have pre-
viously described.31 Briefly, basemonomers 1,4-butane-
diol diacrylate (B4) or 1,5-pentanediol diacrylate (B5)
were polymerized via a Michael Addition reaction
with side chain monomers 3-amino-1-propanol (S3),
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4-amino-1-butanol (S4), or 5-amino-1-pentanol (S5) at
ratios of either 1.05:1, 1.1:1, or 1.2:1 following Support-
ing Information Table S1, yielding acrylate-terminated
polymers. These polymers were then end-capped
with end-capping monomers pentane-1,3-diamine
(E3), 2-((3-aminopropyl)amino)ethan-1-ol (E6), or 1-(3-
aminopropyl)-4-methylpiperazine (E7). As an example,
the polymer made from base monomer B4, side chain
S4, and end-cap E7 is 1-(3-aminopropyl)-4-methyl-
piperazine end-modified poly(1,4-butanediol diacry-
late-co-4-amino-1-butanol) and will be referred to as
447 for the duration of the manuscript. Figure 1 shows
the monomer structures and the polymerization and
end-capping reaction schemes. Gel permeation chro-
matography (GPC) was used to determine polymer size
and polydispersity (Supporting Information Table S1).
The Mn of the polymers varied from 3 to 16 kDa, with
the average being 10 kDa. The PDI of the polymers
varied from1.74 to 8.07 among the polymer types, with
the average PDI being 3.28. The lead polymer, 447, had
aMn of 11345Da, aMw of 36 814 Da, and a PDI of 3.25. It
was chosen as the lead polymer based on its high gene
delivery efficacy. It is possible that the proportion of
polymer chains in the batch that are of relatively high
molecular weight help in increasing the transfection.
Some of our previous work has shown that increased
PBAE polymermolecular weight can increase the bind-
ing affinity of the polymer with DNA and this can
improve gene delivery efficacy.51 Polymer structure
of polymer 447 was characterized via 1H NMR, and
was shown to match previously described structures
(Supporting Information Figure S1).52,53
The in vitroDNAdelivery eﬃcacy of the PBAE library
was assessed in 9L rat gliosarcoma (9L) and F98 rat
glioma (F98) cell lines using plasmid DNA coding for
green ﬂuorescent protein (GFP). Cytotoxicity was mea-
sured using an MTS assay, and transfection was as-
sessed using high-throughput ﬂow cytometry and
ﬂuorescence microscopy. Nanoparticles were formed
by mixing polymer and DNA at mass ratios of 30, 60, or
90 polymer-to-DNA (w/w) in aqueous conditions and
delivering to the cells at a ﬁnal DNA concentration of
5 ng/μL (Figure 2). Of the nanoparticle formulations
tested on 9L cells, ten nanoparticle formulations
Scheme1. Schematic representationof the in vivo study. The 9Lbearing ratswere treatedwith intraperitoneal administration
of ganciclovir twice aday beginningonday 4 and then treatedwith a single CED infusionof PBAE/HSV-tk nanoparticles onday
6 (A). These treated animals showed a signiﬁcant beneﬁt in survival (p = 0.0012 vs control) (BD).
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enabled greater than 50% transfection with less than
20% toxicity (Figure 2A,C). In F98 cells, eight nano-
particle formulations enabled GFP expression in
greater than 50% of cells while maintaining less than
20% toxicity (Figure 2B,D). Compared to Lipofectamine
2000, a leading commercially available nonviral trans-
fection reagent, we found that three PBAE nanoparticle
formulations had superior performance in 9L cells and
15 had superior performance in F98 cells. Interestingly,
the polymer structures that were found to lead to the
highest eﬃcacy in one glioma cell type were not
necessarily the optimal structures for the other glioma
cell type. For example, 453 30 (w/w) transfected
68 ( 3% of F98s, but only 9 ( 1% of 9Ls. In contrast,
457 90 (w/w) shows some signs of potential cytoto-
xicity in F98, but has higher transfection (64( 4%) and
no cytotoxicity in 9Ls. This potential cell-type speci-
ﬁcity based on polymer structure is something that
we have observed with other PBAE structures and
other cell types, such as human endothelial cells.54,55
In considering polymer structure that makes up
the nanoparticles, the E7 end-capping group 1-(3-
aminopropyl)-4-methylpiperazine generally led to im-
proved transfection compared to the E3 or E6 end-
capping groups across the base polymers and glioma
cell types evaluated. This is consistent with prior work
done in other cell types, showing that the E7 end-cap is
generally one of the most eﬀective in our library.34,52,56
Among the non-E7 polymers, 536 60 (w/w) and 536 90
(w/w) nanoparticles had the most robust gene expres-
sion (respectively, 59( 5% and 65( 2% in 9L cells, and
73 ( 3% and 71 ( 5% in F98 cells).
Critically, certain polymeric nanoparticle formula-
tions, such as 447 30 (w/w), transfected both glioma
cells lines at similarly high levels and without any
cytotoxicity. This result matches prior investigation of
PBAEs56 that showed polymers of moderate hydro-
phobicity led to high transfection rates without sig-
niﬁcantly compromising cell viability. On the basis of
the results of this study, we chose polymer 447 at 30
(w/w) as the optimal nanoparticle formulation for both
9L and F98 cells (77 ( 3% and 68 ( 1% transfection,
respectively). Polymer 447 formed nanoparticles with
GFP DNA through self-assembly that were 131( 3 nm
in size and 15( 0.4mV in zeta potential andwithHSVtk
DNA thatwere 138( 4 nm in size and 13( 1mV in zeta
potential (neither particle size nor zeta potential is
statistically diﬀerent between these two formulations).
Even though the plasmid sizes were diﬀerent, the total
nucleic acid mass that was used to form the nanopar-
ticles was the same and this led to nanoparticles with
the same biophysical properties. This ﬁnding also
matches our lab's previous ﬁnding that DNA plasmid
sequence and length does not aﬀect the nanoparticle
size or charge of these PBAE-based nanoparticles with-
in the plasmid DNA size range of 226 kb.56 These
nanoparticles also compared favorably to transfection
with a leading commercially available nonviral trans-
fection reagent, Lipofectamine 2000, which led to 52(
1% and 37 ( 4% transfection in 9L and F98 cells,
respectively (see Supporting Information Table S2 for
full statistical analysis on transfection eﬃcacy).
The polymer that makes up these nanoparticles,
447, has also recently shown robust transfection of
other cancer types, including human brain cancer
cells.34 Although the physicochemical properties that
govern the eﬃcacy and activity of PBAE-based nano-
particles are currently under investigation and likely
Figure 1. Polymer synthesis scheme andmonomer chemical structures. Basemonomers (B) and side chain monomers (S) are
polymerized, and polymers are then end-capped with end-capping monomers (E).
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include the chemical structure andmolecular weight of
the polymer, the polymerDNA binding strength, and
the cellular uptake pathway of the nanoparticles,51,56,57
the exact mechanisms have not yet been fully eluci-
dated. For example, we have seen that two cell types
with very diﬀerent transgene expression rates can show
statistically similar nanoparticle uptake rates.31,34,58 Early
work in our group also suggests that the particular cell
uptake pathway can aﬀect successful transfection rates
with PBAE nanoparticles.57 Nonetheless, we have con-
sistently observed certain trends across various cell
types and culture systems. For instance, the polymers
used here were synthesized using monomer ratios that
yielded products with relatively high molecular weight,
which we and others have shown to have a generally
positive correlationwith transfection eﬃcacy,51,56,59 and
the small molecules used for polymer library synthesis
were chosen based on their transfection eﬃcacy in
other work.51,56,57
PBAE/HSVtk Nanoparticles and a Ganciclovir Prodrug Kill
Glioma Cells in Vitro. We sought to examine the antitu-
mor efficacy of the PBAE/HSVtk nanoparticles in vitro.
Using the optimal nanoparticle formulation 447 at
30 (w/w), we delivered plasmid DNA encoding either
GFP or HSVtk, and treated the cells with GCV at 0, 5, and
50 μg/mL. Viability was assessed quantitatively via cell
counting in 9L and F98 cells (Figure 3B,D). We found
that cancer cell death was dependent on the presence
of both HSVtk and GCV, as HSVtk-transfected cells
were viable when no GCV was present, while GFP-
transfected cells were viable in spite of the presence of
GCV. Specifically, we observed that the nanoparticle-
mediated HSVtk/GCV-induced cytotoxicity was power-
ful, resulting in 106( 3% cell death of 9Ls and 96( 7%
cell death of F98s at 5 μg/mL GCV when the cells were
transfected with HSVtk versus GFP. At 50 μg/mL GCV,
104 ( 5% of 9L cells and 101 ( 2% of F98 cells were
dead. Thesemeasurements of approximately 100% cell
death are consistent with the complete cell death that
was observed by microscopy (Figure 3A,C).
Although the two plasmids used, GFP and HSVtk,
are of diﬀerent size and may result in slightly diﬀerent
transfection rates, the lack of diﬀerence in the physi-
cochemical properties of nanoparticles formed with
diﬀerent types of DNA allows the use of the GFP
plasmid as a nonfunctional control for the HSVtk
Figure 2. PBAE nanoparticles eﬀectively transfect 9L and F98 malignant glioma cells in vitro. All polymers were screened at
30, 60, and 90 (w/w) delivering 0.6 μg of GFP DNA (A and B). Of the nanoparticles tested on 9L and F98 cells, three and 15
formulations, respectively, were found to deliver GFP DNAmore eﬀectively than commercially available transfection reagent
Lipofectamine 2000 (*p < 0.05 versus Lipofectamine with 0.6 μg DNA via one-way ANOVA with Dunnett's post-test).
Fluorescence microscopy shows cells transfected with GFP using PBAE nanoparticles (C and D). Transfection eﬃcacy was
quantiﬁed using ﬂow cytometry. Loss in metabolic activity was quantiﬁed using an MTS assay with colorimetric readout,
measured by a multiplate reader.
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plasmid. As both these types of nanoparticles are
formed with the same total mass of polymer and
vnucleic acid and have the same physicochemical
properties, there is not expected to be a diﬀerence in
polymer- or nanoparticle-induced toxicity between the
two plasmids or their particle distribution. While the
percent of cells transfected with GFP cannot be as-
sumed to be exactly, the same as the percent of cells
positive for HSVtk, the strong cytotoxic eﬀect of GCV in
HSVtk-transfected cells shows that this transfection,
like the GFP transfection, is suﬃcient for a signiﬁcant
biological eﬀect. These data suggest that nanoparticle-
based delivery of the HSVtk gene enables local activa-
tion of GCV into a cell-killing drug, which is known to
cause cell death in malignant glioma lines via activa-
tion of apoptosis.47,60 Moreover, the proportion of
cells killed (approximately 100%) was greater than
the transfection eﬃciency of the glioma cells (<80%),
illustrating the strong bystander eﬀect of the HSVtk/
GCV therapeutic strategy. This is particularly important
in the treatment of a tumor, as even if <100% of the
cancer cells are transfected in vivo, the fraction of
cancer cells that positively express HSVtk can lead to
the apoptosis of neighboring untransfected tumor
cells. This nanoparticle-mediated suicide gene therapy
ﬁnding is consistent with studies done in other labora-
tories with an analogous HSVtk/GCV viral gene therapy
strategy.61,62 Few previous studies have been con-
ducted using nonviral HSVtk gene delivery in cancer
models. Two examples in the literature include Neuro-
tensin (NTS)-polyplex nanoparticles63 used to transfect
triple negative breast cancer cells (MDA-MB-231),
and poly(ethylene glycol)poly(γ-benzyl-L-glutamate)
(PEGPBLG)64 nanoparticles used to transfect oral
squamous cell carcinoma (Tca8113). The transfection
eﬃcacy with these nonviral nanoparticle systems was
lower than in our present study, with only 18% and
30% transfected, respectively. In those cases, the eﬃ-
cacy of GCV treatment was shown to increase cancer
cell death to 50% and 80% through the bystander
mechanism. In contrast, our approach with PBAE
nanoparticles led to 70% transfection eﬃcacy with
100% cell death. To our knowledge, this is the ﬁrst
demonstration of signiﬁcant eﬃcacy and anticancer
eﬀects of PBAE/DNA delivery to treat brain cancer.
PBAE/DNA Nanoparticles Can Be Lyophilized with No Change
in Properties or Efficacy. Lyophilization of nanoparticles
prior to in vivo administration has several benefits.
Drying the nanoparticles enables subsequent reconsti-
tution at a higher concentration, which was particularly
Figure 3. PBAE delivery of HSVtk plasmid enables GCV-mediated killing of malignant glioma cells in vitro. 9L and F98 cells
were transfected with plasmids encoding either GFP or HSVtk and then treated with 0, 5, or 50 μg/mL GCV prodrug. Cells
treated with both HSVtk and GCV exhibit 100% cancer cell killing, measured by cell counting, versus GFP-transfected cells
treated with GCV, showing that GCV-induced cell killing is dependent on the presence of HSVtk. Additionally, HSVtk without
GCV does not kill cells.
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beneficial for intracranial injections, in which volumes
were limited due to size and pressure constraints within
the brain. Lyophilized PBAE nanoparticles can also be
stored for years without losing efficacy34,53 and are
easier to administer, as the user simply needs to add
water and inject. The amount of solutes added to
the particles during formulation is easily adjustable to
ensure that the resulting aqueous suspension is isotonic
after adding water. To ensure that the 447 30 (w/w)
nanoparticles did not lose efficacy after lyophilization,
lyophilized particles were compared to freshly prepared
particles. We compared the size and zeta potential of
447 30 (w/w) nanoparticles and found no significant
difference between freshly prepared and lyophilized
nanoparticles (Figure 4A). We also compared in vitro
transfection of fresh versus lyophilized nanoparticles
and found that measurements of transfection efficacy,
percent of GFP-positive cells, and geometric mean fluo-
rescence showed no statistical difference (p > 0.05)
(Figure 4B). Finally, we imaged fresh and lyophilized
nanoparticles via transmission electron microscopy
(TEM), and found that nanoparticles from each batch
were morphologically similar (Figure 4C,D).
PBAE Nanoparticles Are Safe To Deliver to the Brain. We
assessed the safety of delivering PBAE/DNA nanopar-
ticles to the brain in vivo in both wild type healthy rats
(at day 3 and at day 60 post-nanoparticle infusion) and
9L tumor-bearing rats (atday3post-nanoparticle infusion).
We used 25 μL as the infusion volume, which was
previously shown to be safe.65 PBAE/GFP 447 30 (w/w)
nanoparticleswere injected in10%(w/v) sucroseandwere
tested at 26 μg DNA with 780 μg PBAE. This dose was
found to be safe and was used for subsequent in vivo
studies. The 50 mg/kg GCV injected twice a day was well
tolerated andwas therefore chosen for all efficacy studies.
With the exception of animals euthanized at the
early time point (day 3 post-nanoparticle infusion) for
histopathological analysis, all nontumor-bearing ani-
mals survived until the end of the study (60 days post-
nanoparticle infusion). No signs of neurotoxicity or
paralysis were observed. The histopathology from
day 3 (healthy wild type rats and 9L tumor-bearing
rats) and day 60 (healthy wild type rats) showed no
discernible signs of early or late tissue damage and did
not include cytological changes, edema, gliosis, neuro-
inﬂammation, or necrosis (Supporting Information
Figure S2). These data provide in vivo conﬁrmation of
one of the strengths of biodegradable PBAEs, a strong
safety proﬁle, even when used at high concentration.
Intratumoral Infusion of PBAE/GFP Nanoparticles Leads to
Wide Distribution and Transfection in the Brain. The intratu-
moraldistributionand transfectionofPBAEsnanoparticles
Figure 4. Nanoparticles maintain their physical characteristics and transfection capability following lyophilization. Fresh and
lyophilized nanoparticles showed no statistical diﬀerence (p > 0.05) in their sizes and zeta potentials (A) and showed no
statistical diﬀerence in percent transfection and geometric mean GFP in 9L cells (B). TEM imaging of fresh (C) and lyophilized
(D) nanoparticles shows nanoparticles of the same size and morphology (scale bar = 100 nm).
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after local brain delivery was assessed. To evaluate the
nanoparticle distribution and transfection through
the tumor in vivo, we used nanoparticles containing
Cy5-labeled GFP DNA and examined the distribution of
Cy5þ and GFPþ cells (Figure 5AD). On Day 7, 24 h
post-nanoparticle infusion, the tumor mass was ap-
proximately 2  3 mm, extending from the cortex
toward the ipsilateral caudate/putamen area and in-
vading the left lateral ventricle (Figure 5A). Immuno-
fluorescence staining showed high GFP signal in the
corresponding area of the tumor. Specifically, 24 h
after CED infusion of Cy5-labeled GFP DNA-containing
nanoparticles, the nanoparticles transfected the tumor
mass, while the normal brain remained GFP-negative
(Figure 5B). Importantly, the nanoparticles transfected
cells fairly homogeneously throughout the entire
tumor mass, even distant from the site of infusion
(Figure 5DF).
Limited tumor penetration and low transfection
rates are major obstacles in nonviral gene therapy for
the treatment of brain tumors.37 Transport depends on
physio-anatomic barriers66 and the physicochemical
characteristics of the particle, including its size, shape,
and surface charge. In this study we show that CED
positively aﬀects the biodistribution of the PBAE
nanoparticles compared to bolus injection (Supporting
Information Figure S3). This is due to the creation of a
positive pressure gradient, which creates bulk ﬂuid
movement in the brain interstitium. Tumor-bearing rats
treated with a bolus injection of an equal amount of
PBAE/DNA nanoparticles underwent brain analysis via
immunoﬂuorescence staining as well. Analysis showed
that bolus injection led to transfection in the areas
around the needle-path at the bottom of the tumor,
withmuchof the core andmarginswithout nanoparticle-
mediated gene transfer. After CED infusion, on
the other hand, the nanoparticle-mediated exogenous
gene expression led to positive GFP signal across the
whole tumor mass, from the core to the top, bottom,
and margins. Moreover, the normalized GFP ﬂuores-
cence per pixel of the tumor area (using ImageJ
software) showed a 36% increase by CED infusion
compared to bolus injection (15.8 ( 0.1 RFU vs 11.6
( 0.2 RFU, vs 11.6( 0.2 RFU, p < 0.0001) These ﬁndings
show for the ﬁrst time that PBAE nanoparticles can
penetrate the entirety of the tumor volume and there-
fore are promising for gene delivery when combined
with CED.
PBAE/HSVtk Nanoparticle/GCV Treatment Leads to Prolonged
Survival of 9L Gliosarcoma-Bearing Rats. After demonstrat-
ing the in vitro efficacy of PBAE/HSVtk nanoparticles in
F98 and 9L glioma cells and the in vivo safety of PBAE
nanoparticles for intratumoral transfection, we pro-
ceeded to test their in vivo therapeutic efficacy in 9L
tumor-bearing rats (Scheme 1). 9L gliosarcoma is a
highly aggressive syngeneic glioma model67,68 and is
well-known as a challenging survival model due to its
fast rate of growth. Thismodel, although rodent-based,
has achieved undisputed clinical relevance as it has
been used as a preclinical model for multiple clinical
trials in the investigation of novel chemo and immu-
notherapies, drug delivery strategies, and gene
therapies.6974 Animal survival after treatment with
PBAE/HSVtk nanoparticles in combination with GCV
was significantly longer compared to the untreated
control group (p = 0.0012) (Figure 6). PBAE/HSVtk
nanoparticles were also found to provide survival ben-
efits compared to all the other control groups: GCV
Figure 5. Local brain delivery of PBAE/GFP Nanoparticle via CED leads to eﬀective tumor transfection in vivo. Coronal section
of a 9L tumorbearing rat brain at 7 dayspost PBAE/GFP infusion showing the tumor region (A, scale bar = 2mm). Fluorescence
microscopy images show GFPþ transfected cells in the tumor area (B, scale bar = 2 mm). Enlarged area shows a wide
distribution of GFPþ cells within the entire tumor area including the periphery (C, scale bar = 500 μm). The colocalization of
GFP andCy5 shows that the nanoparticles penetrate into the cells and successfully transfect them (DF, scale bar: 50 μm). Re,:
Cy5; green, GFP; blue, DAPI.
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only (p = 0.0102), PBAE/GFP þ GCV (p = 0.027), and
HSVtk DNAþ GCV (p = 0.027).
Considering that 9L is characterizedby an exponential-
Gompertzian curve of growth after 6 days,67,68,75 such a
statistically signiﬁcant beneﬁt in survival in the group
treated with PBAE/HSVtk plus GCV is promising. The
eﬃcacy of the HSVtk/GCV paradigm has previously
been shown in the 9Lmodel using other strategies76,77
and the bystander eﬀect and a resulting immune
response can both contribute to the overall cytoto-
xicity of the PBAE/HSVtk GCV treatment.78,79 Due to the
positive relationship between the bystander eﬀect and
the percent of HSVtk transfected cells,50 the improve-
ment in survival observed here is highly indicative of
strong PBAE transfection eﬃcacy in vivo matching
what was also observed in vitro. PBAE-based gene
delivery has a potential role as alternative strategy to
virus mediated gene therapy for glioblastoma.
HSVtk/GCV therapy has previously been used in
brain tumor treatment clinical trials with retroviral8082
and adenoviral83 vectors with limited success in
progression-free and overall survival. This has been
attributed to poor distribution of the carrier and limited
delivery of HSVtk into the tumor. The HSVtk/GCV
system has also been used to investigate the eﬃcacy
of nonviral vectors in Phase III studies conducted
with cationic liposomal vectors, which showed, via
positron emission tomography with a 124I-labeled spe-
ciﬁc substrate for HSV-1, presence of thymidine kinase
in one out of ﬁve patients.84 A subsequent study using
liposomes had encouraging results by showing reduc-
tion of the tumor volume mass in two out of eight
patients.85 Yet, nonviral gene therapy is generally
considered less eﬃcient than viral gene therapy.86
While siRNA delivery nanomedicine approaches have
been progressing rapidly, including approaches
such as spherical nucleic acids for the treatment of
glioblastoma,87 DNA delivery has been more challeng-
ing. This is likely due to in large part to the much
larger size of DNA as a nanomedicine drug cargo
and the need for it to be delivered into nucleus rather
than just into the cytoplasm.84 Due to the wide tumor
penetration, high exogenous gene expression, and
bystander eﬀect capabilities, the PBAE/HSVtk nano-
particles may be able to overcome the previously
encountered limitations and be a promising new
nanomedicine for brain cancer.
CONCLUSIONS
In this work, we have developed a new gene transfer
nanomedicine that causes the expression of suicide
gene herpes simplex virus type I thymidine kinase
(HSVtk) within brain tumor cells in vitro and in vivo.
Biodegradable nanoparticles were synthesized, char-
acterized, and utilized to treat malignant glioma using
convection-enhanced delivery (CED). The lead polymer
structure, poly(β-amino ester) 1-(3-aminopropyl)-4-
methylpiperazine end-modiﬁed poly(1,4-butanediol
diacrylate-co-4-amino-1-butanol), formed DNA nano-
particles with suitable biophysical properties for intra-
cellular delivery and a wide biodistribution when
injected intracranially. CED led to improved levels of
tumor transfection. These PBAE/HSVtk nanoparticles
combined with systemic administration of ganciclovir
as a prodrug led to a signiﬁcant increase in survival in a
9L glioma model (p = 0.0012 vs control). Our results
provide the ﬁrst demonstration of a successful nonviral
nanomedicine method for HSVtk/GCV treatment of
brain cancer.
MATERIALS AND METHODS
Polymer Materials. Monomers used for polymer synthesis
were purchased as follows: 1,4-butanediol diacrylate (B4; Alfa
Aesar, Ward Hill, MA); 1,5-pentanediol diacrylate (B5; Monomer-
Polymer and Dajac Laboratories, Trevose, PA); 3-amino-1-
propanol (S3; Alfa Aesar); 4-amino-1-butanol (S4; Alfa Aesar);
5-amino-1-pentanol (S5; Alfa Aesar); pentane-1,3-diamine (E3;
TCI America); 2-(3-aminopropylamino)ethanol (E6; Sigma-
Aldrich); 1-(3-aminopropyl)-4-methylpiperazine (E7; Alfa Aesar).
Lipofectamine 2000 was purchased from Invitrogen (Carlsbad,
CA) and used according to manufacturer's instructions. The
pEGFP-N1 plasmid (GFP) was purchased from Elim Biopharma-
ceuticals and amplified by Aldevron (Fargo, ND). Herpes simplex
virus type 1-derived thymidine kinase (HSVtk) gene was cloned
into the pcDNA3.1 vector (Life Technologies) according to
the manufacturer's protocols. Label IT Tracker Cy5 Kit was
purchased from Mirus Bio (Madison, WI). For staining, 2-(4-
amidinophenyl)-1H -indole-6-carboxamidine (DAPI) was pur-
chased from Life Technologies, propidium iodide (PI) was
purchased from Invitrogen (Carlsbad, CA), and the conjugated
antibody anti-Ki67 Alexa Fluor 647 (rabbit anti-rat 1:50) was
purchased from Cell Signaling Technology (Beverly, MA).
Figure 6. PBAE/HSVtk nanoparticles and ganciclovir (GCV)
extend survival in a 9L glioasarcoma model. KaplanMeier
plots of F344 rats that were implanted with 9L and either
given no treatment (9L Control, n = 16); 50 mg/kg twice a
day of systemic administration of GCV on days 413 (GCV
Alone, n = 8); intracranial infusion of PBAE/GFP nanoparti-
cles plus systemic administration of GCV (NP-GFP þ GCV,
n = 8); intracranial infusion of HSVtk DNA plus systemic
administration of GCV (DNA þ GCV n = 8); or intracranial
infusion of PBAE/HSVtk nanoparticles plus systemic admin-
istration of GCV (NP-HSVtk þ GCV, n = 8). The median
survival of the group receiving PBAE/HSVtk nanoparticles
in combinationwithGCV is signiﬁcantly longer compared to
that of the untreated control group (p = 0.0012).
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CellTiter 96 AQueous One MTS assay was purchased from
Promega (Fitchburg, WI). Ganciclovir was purchased from both
Invivogen (San Diego, CA) and Euroasian Chemicals PVT LTD
(Lower Parel, Mumbai, India).
Polymer Synthesis. PBAEs were synthesized using a two-step
reaction (Figure 1) in a manner similar to Bhise et al.88 Base
monomers B4, B5, or B6 were each polymerized by Michael
Addition of one of the side chain monomers S3, S4, or S5 at
ratios following Supporting Information Table S1, for 24 h at
90 C in the absence of solvent. Monomer acrylate-to-amine
molar ratios used for synthesis ranged from 1.2:1 to 1.05:1. For
the second step of synthesis, the diacrylate-terminated base
polymers (B-S) were dissolved in anhydrous tetrahydrofuran
(THF, Sigma) at 100 mg/mL and combined with 0.2 M amine-
containing small molecules (E3, E6, or E7) as polymer end-
capping groups. The reaction was conducted for 1 h at room
temperature while shaking. Polymers were then purified to
remove excess monomer via precipitation in diethyl ether.
The ether was decanted to collect polymer, the polymer was
washed again with ether, the ether was decanted, and then the
polymer was allowed to dry under vacuum for 48 h. The neat
polymers were then dissolved in dimethyl sulfoxide (DMSO) at
100 mg/mL and stored at 20 C in small aliquots to limit
freezethaw cycles. The molecular weight and polydispersities
of the polymers were determined by gel permeation chroma-
tography (GPC; Waters, Milford, MA) in BHT-stabilized tetra-
hydrofuran with 5% DMSO and 1% piperidine. Number-
averaged and weight-averaged molecular weights (Mn and
Mw, respectively) were measured using polystyrene standards
(Supporting Information Table S1). Purity of the leading poly-
mer, 1-(3-aminopropyl)-4-methylpiperazine end-modified poly-
(1,4-butanediol diacrylate-co-4-amino-1-butanol) (447), was con-
firmed by 1H NMR spectra (Supporting Information Figure S1).
Preparation of Cy5-Labeled DNA. GFP DNA was labeled with Cy5
using the Label IT Tracker Cy5 Kit following manufacturer
instructions. The amount of Cy5 labeling was measured to be
approximately one dye molecule per 205 base pairs.
Cell Culture. F98 glioma cells were provided from R. Barth
(Ohio State University, Columbus, OH) and the 9L gliosarcoma
line was obtained from the Brain Tumor Research Center
(University of California, San Francisco, CA). Cells were grown
in high glucose Dulbecco's modified Eagle's medium (DMEM;
Gibco Life Technologies, Carlsbad, CA) supplemented with 10%
fetal bovine serum (FBS; Sigma-Aldrich), 0.8 mM L-glutamine,
and 1% penicillinstreptomycin (Gibco Life Technologies,
Carlsbad, CA). Cells were cultured at 37 C in a humidified
incubator with 5% CO2.
In Vitro DNA Delivery to Glioma Cells Utilizing PBAE Nanoparticles.
One day prior to transfection, 9L and F98 cells were plated in
96-well cell culture plates at a cell density of 10 000 cells/well in
100 μL of complete medium, and allowed to adhere at 37 C
overnight. For nanoparticle preparation, following previously
reported protocols,34,88 GFP DNA was diluted to 60 μg/mL in
25 mM sodium acetate pH 5 buffer (NaAc). PBAEs were diluted
from their stock solutions in DMSO in 25mMNaAc and added to
DNA solutions at PBAE/DNA mass ratios (w/w) of 30, 60, or 90.
Polymers were added to DNA 1:1 (v/v), mixed via pipetting, and
incubated at room temperature for 10 min to allow for self-
assembly, which has previously been shown to be sufficient
time for DNA binding to the polymer.56 Nanoparticles (20 μL) in
NaAcwere added directly to the cells that were in 100 μL/well of
cell culture medium in 96-well plates (final DNA concentration
of 600 ng/well). Nanoparticles were incubated with the cells for
2 h at 37 C, after which the media was removed and replaced
with fresh, complete media. Four replicates were evaluated for
each transfection condition. For lyophilized nanoparticle for-
mation and evaluation (Figure 4), nanoparticles were initially
formed as described above, including allowing 10 min for self-
assembly. Subsequently, D-sucrose was added as a cryoprotec-
tant to a final concentration of 30 mg/mL sucrose, the nano-
particles were frozen at80 C, and they were lyophilized as we
have recently described.53 Lyophilized nanoparticles were
stored at20 C until use and were then reconstituted in sterile
water and used at the same concentration as freshly prepared
nanoparticles.
Evaluation of Transfection by Flow Cytometry and Fluorescence Micros-
copy. Transfection efficacy was evaluated by measuring the
percentage of cells expressing the exogenously delivered GFP
DNA. Fluorescence microscopy images were obtained using a
Zeiss Axio observer A1 microscope with a Zeiss Axiocam MRm
camera using AxioVision Release 4.8.2 software. Transfec-
tion efficacy was evaluated by microscopy after 48 h at 5
magnification.
Flow cytometry was completed 48 h following transfection
using an Intellicyt high-throughput autosampler attached to an
BD Accuri C6 ﬂow cytometer (emission ﬁlter: 530/30 nm).
Hypercyt software was used to assign events to each well and
FlowJo 7 software (Treestar) was used to analyze the ﬂow
cytometry results. Plates were prepared for ﬂow cytometry by
trypsinization using 30 μL of 0.05% TrypsinEDTA, followed
by addition of 170 μL of a solution of 2% FBS in PBS. Samples
were transferred to round-bottom 96-well plates and centri-
fuged, and 170 μL of volume was removed. Cells were then
resuspended via pipetting and loaded onto the Hypercyt
autosampler.
Measurement of Cytotoxicity. Nonspecific cell toxicity was
defined as the loss of metabolic activity in each well follow-
ing transfection. Cell toxicity was determined at 24 h post-
transfection using a CellTiter 96 AQueous One MTS assay follow-
ing manufacturer's instructions. A BioTek Synergy 2 Microplate
Reader was used to read absorbance at 490 nm, and cell toxicity
was determined by normalizing the metabolic activity values of
treated wells to untreated wells.
Evaluation of HSVtk/GCV-Induced Cytotoxicity in 9L and F98 Glioma Cell
Lines. Cells were transfected as described above using polymer
447 at 30 (w/w), using either HSVtk or GFP DNA (n = 4). GCVwas
added to the cell culture medium at 24 h post-transfection at
concentrations from 0 to 50 μg/mL and replenished every
2 days. At 5 days post-transfection, cells were stained with PI,
fixed, and then stained with DAPI. Each well was photographed
at 5magnification to capture PI and DAPI fluorescence as well
as a brightfield image using a Zeiss Axio observer A1 micro-
scope with a Zeiss Axiocam MRm camera using AxioVision
Release 4.8.2 software. Cells positive for PI and/or DAPI were
counted using ImageJ v1.47 software. PI cell counts were
subtracted from DAPI cell counts to remove dead cells from
the total cell count, and then the total cell count of each well
was normalized to that of untreated wells.
Nanoparticle Physical Characterization. The hydrodynamic radius
and zeta potential of the leading nanoparticle formulation,
447 30 (w/w), was determined via dynamic light scattering
(DLS) using a Malvern Zetasizer NanoZS (Malvern Instruments,
Malvern, U.K.). Fresh and lyophilized nanoparticles were formed
as previously described for transfection, and then diluted into
PBS at a 1:6 (v/v) dilution in order to better approximate the
physiological salt concentration and pH that particles would
experience in cell culture or in an organism. Tomeasure particle
size, the intensity-weighted Z-average of the particle diameter
is reported in nm. Zeta potentials were analyzed using the
Smoluchowski model and average electrophoretic mobilities
were measured at 25 C at pH 7.4.
Transmission Electron Microscopy. Transmission electronmicros-
copy (TEM) was used to image 447 30 (w/w) nanoparticles
using a Philips/FEI BioTwin CM120 transmission electron micro-
scope. Nanoparticles were formed as described for transfection,
and 5 μL of the nanoparticle solution was loaded onto a carbon-
coated copper TEM grid and allowed to dry completely prior to
imaging.
Animals. Female F344 rats, weighing 125175 g each (Harlan
Bioproducts, Indiana, IN), were housed in standard facilities and
were provided with ad libitum access to food and water. The
policies andguidelinesof the JohnsHopkinsUniversityAnimal Care
and Use Committee were strictly followed throughout the study.
Tumor Implantation. F344 rats were intracranially implanted
with 9L gliosarcoma, whichwasmaintained and passaged every
23 weeks. For surgical intracranial implantation, the tumor
was removed from the carrier animal, cut into 2mm3pieces, and
placed in sterile 0.9% saline on ice as previously described.89
Rats were anesthetized with an intraperitoneal injection of
35 mL/kg of a stock solution containing ketamine HCl
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(75 mg/kg; 100 mg/mL), xylazine (7.5 mg/kg; 100 mg/mL), and
ethanol (14.25%) in sterile 0.9% NaCl. For the orthotopic tumor
inoculation, the head was shaved and prepared with alcohol
and Prepodyne solution (DeLaval, Inc.). To expose the sagittal
and coronal sutures, a midline scalp incision was made. A small
hole was made using an electric drill in the skull centered 3 mm
lateral to the sagittal suture and 5 mm posterior to the coronal
suture. The superior sagittal sinus was carefully avoided. Under
microscopic magnification, a dural opening and then a cortical
opening were made. A small area of cortex and white matter
was resected. Once hemostasis was achieved, a single tumor
piece (2mm3) was placed into the resection cavity. The skin was
then closed with surgical staples. All surgical procedures were
performed using standard sterile surgical technique.
In Vivo Nanoparticle Administration. Under full anesthesia, 6 days
after tumor inoculation, the original incision was opened and
the original burr hole was located. For Convection-Enhanced
Delivery (CED), a 25-gauge needle was stereotactically placed at
a depth of 3 mm into the rat striatum. The infusion was
performed using an UltraMicroPump (UMP3) with SYS-Micro4
Controller (World Precision Instruments, Inc., Sarasota, FL) at a
rate of 1 μL/min for 25 min. After the injection, the needle was
maintained in the cortex for another 5 min to avoid backflow.
Following needle removal, the incision was stapled and the
animal was allowed to awaken and recover. Bolus administra-
tion delivered the same volume of nanoparticles by manual
injection as previously described.89
Throughout the study, three types of DNA were complexed
with 447 30 (w/w) to form nanoparticles and used in vivo in
lyophilized form: (1) GFP, (2) Cy5-labeled GFP, and (3) HSVtk. The
nanoparticles were stored in 20 C and were resuspended in
water prior to injection. The particles were injected both by
bolus (manual injection) or infused by CED. The twomethods of
nanoparticle administration were compared using 12 tumor-
bearing rats infused with PBAE/GFPs 6 days after tumor im-
plantation. The animals were euthanized at 24 h postinfusion
and the brains were ﬁxed in formalin for imaging. The eﬃcacy
study was performed using CED.
In Vivo Safety Studies. The safety of intracranial injection of
PBAEs was evaluated. PBAE 447/GFP DNA nanoparticles (26 μg
DNA/780 μg polymer) were infused in a volume of 25 μL using
CED in six wild type healthy rats and three 9L tumor-bearing rats
for a total number of 9 rats. All rats were observed daily for any
signs of neurotoxicity. Three animals from each group were
euthanized 3 days after nanoparticle infusion, while the remain-
ing nontumor-bearing animals were observed for 60 days after
nanoparticle infusion and then euthanized. Subsequently, their
brains were harvested and placed in formalin for histopatho-
logical analysis. Specifically, the brains were cut in 3 slices of
2 mm: one centered on the site of the injection and the other
two centered 2 mm anteriorly and posteriorly from it.
The safety of systemically injected ganciclovir was assessed
in 6 rats for 10 days: 3 rats were treated with intraperitoneal
administration of 50 mg/kg once a day and the other 3 with
50 mg/kg twice a day for 10 days. Rats were evaluated daily for
signs of pain and distress, including ruﬄed fur, dehydration,
hunched position, weakness, lethargy, immobility, lack of co-
ordination, labored respiration, or cyanosis according to the
Johns Hopkins Animal Care and Use Guidelines. At the end of
the study, the brains were ﬁxed, sectioned, and processed for
light microscopic analysis to determine histopathology and to
evaluate tissue damage.
Efficacy Studies. For intracranial implantation, 48 F344 rats
(24 rats for the first study and 24 for the second) were
anesthetized and received tumor as described above. Six days
after tumor implantation, when tumor area was approximately
2 3mm2, the rats were randomized into the following groups:
Control group, which received an intracranial infusion of 25 μL
of saline by CED (n = 16); GCV group which received intraper-
itoneal administration of 50 mg/kg of GCV twice a day (n = 8);
NP-GFP þ GCV group, which received intracranial infusion of
PBAE/GFP nanoparticles plus intraperitoneal administration of
GCV (n = 8); DNA þ GCV group, which received intracranial
infusion of HSVtk DNA plus intraperitoneal administration of
GCV (n = 8); and the NP-HSVtk þ GCV group, which received
intracranial infusion of PBAE/HSVtk nanoparticles plus intraper-
itoneal administration of GCV (n = 8).
GCV was administered for 10 days, from Day 4 to Day 13, i.e.
starting 4 days after tumor implantation and 2 days before
PBAE/HSVtk infusion due to the aggressive nature of the 9L
glioma, as described previously.48 The animals were monitored
daily and assessed for neurological impairment. The animals
were perfused as they became moribund and brains were
placed in formalin for histological analysis.
Brain Imaging. Immunofluorescence staining of the in vivo
transfection was assessed. A total of 6 rats were used for
imaging in vivo transfection 24 hr post-infusion via CED.
Animals were infused at 6 days after tumor implantation with
Cy5-labeled GFP DNA utilizing the DNA/polymer ratio used for
the efficacy study. A comparison of nanoparticle delivery via
bolus injection and CED infusion was subsequently conducted.
The image analysis was performed with ImageJ as previously
described90 and the whole tumor was considered as the region
of interest (ROI). The boundaries of the tumor area were
determined by a neuropathologist via blind analysis of H&E
and DAPI stained slides. The corrected total cell fluorescence
(CTCF) intensity of the whole tumor area, both after CED
infusion and after bolus injection, was compared and calculated
as follows: integrated density  (area of selected cell  mean
fluorescence of background readings), normalized by the num-
ber of pixels in the tumor area. To evaluate PBAE distribution
between the two administration methods and how this might
affect transfection efficacy, 12 9L tumor-bearing rats were
divided into two groups: a CED group (n = 6) and an intracranial
bolus injection group (n = 6). Cy5 labeled GFP-nanoparticles
were infused via CED infusion or bolus injection on Day 6 and
the rats were sacrificed 24 h later. The animals were anesthe-
tized and perfused with 0.1 M phosphate-buffered saline (PBS),
followed by 4% paraformaldehyde in 0.1 M PBS solution. The
brain was immediately removed from the skull and transferred
to 4% paraformaldehyde at 4 C for 24 h.
Immunohistochemistry. The brains, fixed in 4% paraformalde-
hyde at 4 C for at least 24 h, were cryoprotected by sinking in
30% sucrose in 0.1 M PBS for 3 days and then embedded in
Optimal Cutting Temperature compound (OCT) compound.
Cryosection slides were prepared at 10 μm using a Leica
CM1905 cryostat. The slices were imaged to assess transfection
byconfocal laser scanningmicroscope (Leica TCSSP5Microsystems)
and captured with Axiovision software (Axiovision Rel 4.9).
Data Analysis and Statistical Methods. Transfection efficacy of
PBAE nanoparticles was compared to Lipofectamine 2000 using
One-way ANOVA and Dunnett posttests (GraphPad Prism 5.0).
Comparisons of fresh and lyophilized nanoparticles were
conducted using two-tailed t tests (GraphPad Prism 5.0). The
statistical analysis for survival was completed using Kaplan
Meier survival plots (GraphPad Prism 5.0), and the survival
curves were compared using the Log-rank (Mantel-Cox) test.
p < 0.05 was considered statistically significant in all cases.
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